FF-10101

Target: This ligand targets FMS-like tyrosine kinase 3 (FLT3), including mutant FLT3 kinase forms in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for FMS-like tyrosine kinase 3 (FLT3), including mutant FLT3 kinase forms. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings FMS-like tyrosine kinase 3 (FLT3) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Target Degradation: FF-10101 can be used as a ligand component to build PROTACs that recruit an E3 ligase and drive ubiquitination of a chosen target protein. This enables systematic evaluation of degradation potency, including dose–response behavior, time dependence, and dependence on the ubiquitin–proteasome pathway in cellular assays.

• E3 Ligase Recruitment Optimization: Incorporating FF-10101 into PROTAC architectures supports engineering studies aimed at improving productive ternary complex formation. Researchers can vary linker length, attachment position, and steric constraints to tune cooperativity between the target and E3 ligase, thereby enhancing degradation efficacy while minimizing off-target stabilization.

• Structure–Activity Relationship Studies: FF-10101-based PROTACs are suitable for SAR mapping to identify how ligand geometry and chemical features influence degradation. By comparing analogs that preserve binding while altering physicochemical properties, investigators can correlate changes in target engagement with shifts in degradation kinetics and maximal extent of protein loss.

• Mechanistic Validation of Degradation: FF-10101-containing PROTACs can be used to interrogate degradation mechanisms using orthogonal perturbations. Experiments such as proteasome inhibition, E3 ligase knockdown, and competition with free ligands help confirm that observed decreases reflect targeted ubiquitin-mediated turnover rather than transcriptional or translational effects.

FF-10101 is listed as a potential target-protein ligand, but a reliable target assignment for PROTAC design was not confirmed from the supplied identifiers. Use should be restricted to cases where independent binding data are available. This molecule is described in detail below.

Structure: The structure of FF-10101 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.